Francis Medical Advances Vanquish Prostate Ablation System With New Clinical and Conference Momentum

Francis Medical is in the spotlight this week as it advances its Vanquish Water Vapor Ablation System, an FDA-cleared focal therapy for targeted prostate tissue ablation. The company underscored the system’s differentiated mechanism, which uses high thermal energy transfer during water-to-vapor phase change at around 100°C to induce cell death in prostate tissue.

Vanquish is being positioned as a minimally invasive, transurethral option intended to expand focal therapy choices in prostate care. Francis Medical’s communications point investors and clinicians to its website for scientific background and safety information, reinforcing a focus on evidence, procedure-based revenues, and recurring system and consumable sales.

A major theme this week is clinical validation, with Francis Medical highlighting its presence at the European Association of Urology Congress 2026. At EAU26, the company hosted a dinner event featuring Dr. Arvin K. George, who presented patient experience data from the multi-center VAPOR 2 Study evaluating Vanquish in real-world urology practice.

VAPOR 2 is described as a novel, multi-center clinical trial studying Vanquish as a transurethral thermal water vapor technique for ablating prostate tissue. Early data on the first 110 patients with 12‑month follow‑up have reportedly been shared, signaling an expanding evidence base around safety, efficacy, and patient experience outcomes for the device.

Francis Medical’s messaging emphasizes Vanquish as a prescription-only, FDA-cleared device, with the clinical trial progress supporting its positioning as an emerging evidence-based approach in minimally invasive urology. Engagement with leading urologists at EAU26 suggests a strategy focused on specialist education and clinical proof rather than direct-to-consumer marketing.

From a financial and strategic perspective, growing clinical data and heightened professional awareness could be important for driving physician adoption, reimbursement discussions, and long-term revenue growth. Overall, the week marked steady momentum for Francis Medical as it combines scientific communication, clinical trial visibility, and conference engagement to support broader commercialization of its Vanquish system.